Followers | 800 |
Posts | 56098 |
Boards Moderated | 4 |
Alias Born | 08/11/2002 |
Monday, March 24, 2008 1:36:45 PM
Dan;
Following along on our conversation this morning I would like to confirm our dialogue to date and offer you some suggestions as to how you can effectively address your shareholders and invite long term investment into Planet Health.
I know that the market will reward you with much higher stock prices if this is indeed your intent. You could easily be trading on the OTCbb right now in a fully reporting state, commanding shares prices of .20 - .30 cents per share, and attracting a different investor profile. This is not pie in the sky thinking, it has to do with the market recognizing your company and beginning to invest in it. You can effect change here at your will, anytime you like.
You have said you will not be changing the share structure of PNHL for the foreseeable future. You have said no adjustments to the Authorized are contemplated, nor is there any risk of a Reverse Split planned now or for the foreseeable future. You have said that there are no convertible debentures issued agsint your stock, nor will there be.
You have said that it is your intention to cause the stock to appreciate in value through building out the company fundamentally.
Your shareholders are waiting for you to address the above issues, and I have told you this. You have confirmed that you recognize this and have said you will act very shortly. The whole idea of success on this venture, in terms of addressing your shareholders, is one of transparency. If you solve this issue, the world will be your oyster.
Updating Pinksheets.com would be a first step here, confirming the share structure, and issuing a Press Release at the same time through Businesswire. That would start the ball rolling. Complying further with Pinksheets as regards their filing methodologies would further point PNHL in the right direction.
We look forward to your upcoming PR's on the above and the next stage in your fundamental buildout.
Thank you,
fringe_remnant
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM